Given the prevalence of osteolytic bone disease in multiple myeloma (MM), novel therapies targeting bone microenvironment are essential. Previous studies have identified activin A to be of critical importance in MM-induced osteolysis. Lenalidomide is a known and approved treatment strategy for relapsed MM. Our findings demonstrate that lenalidomide acts directly on bone marrow stromal cells via an Akt-mediated increase in Jun N-terminal kinase-dependent signaling resulting in activin A secretion, with consequent inhibition of osteoblastogenesis. Here, we attempted to augment the antitumor benefits of lenalidomide while overcoming its effects on osteoblastogenesis by combining it with a neutralizing antibody to activin A. Increased activin A secretion induced by lenalidomide was abrogated by the addition of activin A-neutralizing antibody, which effectively restored osteoblast function and inhibited MM-induced osteolysis without negating the cytotoxic effects of lenalidomide on malignant cells. This provides the rationale for an ongoing clinical trial (NCT01562405) combining lenalidomide with an anti-activin A strategy.
INTRODUCTION
Implicit in modern cancer treatment is the call for efficient multifaceted therapies that effectively target malignant cells as well as the tumor microenvironment. Such a concept is of particular relevance to multiple myeloma (MM), in which the majority of patients develop osteolytic bone lesions consequent to severe imbalances in bone resorption and formation occurring within the microenvironment. [1] [2] [3] Accordingly, combinations that succeed in selectively inhibiting processes relevant to osteolysis in addition to MM cell viability would be of great therapeutic potential to the MM patient.
Here, we investigated the benefits of combining lenalidomide with a neutralizing antibody to activin A. Lenalidomide is a proven immunomodulatory analog of thalidomide 4 that, while displaying both direct antitumor activity as well as indirect inhibition of osteoclastogenesis, [4] [5] [6] lacks an anabolic bone effect. Conversely, activin A is an extracellular protein complex critical in MM tumorinduced osteolysis, whose sequestration has been recently demonstrated by us to restore bone architecture and reduce tumor burden in vivo. 7 We therefore hypothesized that concurrent treatment of both the bone microenvironment and MM cells with an activin A-neutralizing antibody and lenalidomide, respectively, may result in disease control along with a positive impact on bone disease.
Interestingly, our studies revealed that lenalidomide increases activin A secretion from bone marrow stromal cells (BMSCs), in part via an indirect activation of the previously implicated Jun N-terminal kinase (JNK) signaling pathway. 7 This resulted in a negative effect on osteoblastogenesis similar to that observed with increasing concentrations of activin A. 7 The addition of the activin A-neutralizing antibody, which effectively sequestered activin A, was able to overcome this while maintaining the cytotoxic benefits of lenalidomide. Our work therefore confirms the validity of combining an activin A-neutralizing antibody with lenalidomide in the treatment of MM.
MATERIALS AND METHODS

Cell lines, patient samples and reagents
Dexamethasone-sensitive Human MM cell lines (MM.1S) were provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA). The human bone marrow (BM) stroma-dependent MM cell line (MOLP5) was provided by Dr Y Matsuo (Okayama, Japan). 8 BM aspirates from MM patients were obtained following approval from the Massachusetts General Hospital Institutional Review Board. After mononuclear cell separation, MM cells were purified by positive CD138 (Syndecan-1) Micro Bead selection as previously described. 9 For generation of BMSC, mononuclear cells were placed in 25-mm 2 culture flasks in a-minimum essential medium containing 20% fetal bovine serum, 2 mmol/l L-glutamine (CORNING Cellgro, Manassas, VA, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (CORNING Cellgro). Once confluent, the cells were trypsinized and passaged as needed. For experiments, BMSCs were incubated in 96-and 6-well culture plates and grown to confluence. For coculture experiments, BMSCs were incubated in 96-well culture plates (1 Â 10 4 BMSCs/well) for 24 h; after washing, MM cell lines were added to the wells (2 Â 10 4 cells/well) and incubated with either the media or increasing doses of lenalidomide and activin A-neutralizing antibody at 37 1C. To differentiate osteoblasts (OB), BMSCs were grown to confluence and cultured with osteoblastogenic media containing a-minimum essential medium with 20% fetal bovine serum, 2% penicillin streptomycin (CORNING Cellgro), b-glycerol phosphate at 2.16 mg/ml, ascorbic acid at 0.05 mg/ml, and dexamethasone at 10 nmol/l (Sigma-Aldrich, St. Louis, MO, USA). OB viability was evaluated by Alamar Blue assay. Following cell viability analysis, wells were washed with phosphate-buffered saline once, fixed and washed with distilled water, and stained with alkaline phosphatase (ALP) as previously described. 10, 11 To assess the effects of MM cells on OB differentiation, we cocultured MOLP-5 MM cells, 10 000 cells/ml, with or without lenalidomide and/or activin A-neutralizing antibody. MM cell proliferation in coculture was assessed by thymidine uptake as previously described.
12 Activin A-neutralizing antibody (R&D Systems Inc., Minneapolis, MN, USA), SP600125 (Sigma-Aldrich) (selective inhibitors of c-Jun N-terminal kinase) and Akt Inhibitor VIII (Calbiochem, EMD Biosciences, Inc., Darmstadt, Germany) (isozymes specific to Akt1/2) were used at concentrations of 1 mg/ml, 20 mM and 1 mM, respectively, unless otherwise specified. Lenalidomide was obtained from Selleck Chemicals LLC (Houston, TX, USA) and dissolved first in dimethyl sulfoxide at 10 mM, and then in culture medium before use at varying working concentrations.
Enzyme-linked immunosorbent assay BM plasma from MM patients as well as supernatant from OB and BMSCs were collected and stored at À 80 C. Enzyme-linked immunosorbent assays (ELISAs) for activin A (R&D Systems) were performed according to manufacturer instruction.
Western blotting
Confluent cells were harvested at specific time points, and lysed in lysis buffer as previously described. 13 Samples were then subjected to SDS-polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane and immunoblotted with antibodies against phospho-SMAD1/5/8, SMAD5, phospho-SMAD2, SMAD2/3, phospho-P38, P38, phospho-c-Jun, c-Jun, phospho-JNK, JNK, phospho-Akt, Akt, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), ERK1/2 (Cell Signaling Technology, Danvers, MA, USA) and phospho-ERK1/2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Antigen-antibody complexes were detected by enhanced chemiluminescence (GE Healthcare Biosciences, Pittsburgh, PA, USA). 
Statistical analysis
All in vitro experiments were performed in triplicate and repeated at least three times; a representative experiment was selected for figures. Statistical significance of differences were determined using two-tailed Student's t-test, with minimal level of significance Po0.05.
RESULTS
Lenalidomide induces activin A secretion by BMSC via activation of the JNK pathway We evaluated the effect of lenalidomide treatment on activin A secretion by ELISA. MM patient-derived BMSCs were cultured for 48 h in the presence of lenalidomide (2 and 10 mM), and an ELISA for activin A was performed on the supernatant. The values (pg/ml) were normalized to proliferation rates (CPM1). We observed a significant increase in activin A levels after lenalidomide treatment ( Figure 1a ). We next evaluated activin A concentrations in the plasma of BM aspirates obtained from MM patients who were on lenalidomide treatment. Samples were taken before starting lenalidomide and after several months of treatment. Patients were on low doses of lenalidomide in the absence of steroids (10-15 mg) and the average duration of treatment was 33 weeks. Of the six patients tested, activin A showed a trend toward increasing levels in four patients, two of which were statistically significant, confirming that lenalidomide results in increased activin A secretion ( Figure 1b ) in vivo from patient-derived samples.
Lenalidomide inhibits OB differentiation and induces activin A secretion by OB Given the known effects of activin A on bone remodeling, 5 we next investigated effects of lenalidomide on osteoblastogenesis. OB were differentiated for 1 week in the presence of lenalidomide (10 mM), and ALP activity was detected with a chromogenic substrate and normalized to the number of viable cells quantified by Alamar Blue assay to establish API (ALP index). API measurements showed a decrease in activity when OB were differentiated in the presence of lenalidomide ( were analyzed for activin A secretion by ELISA before and after the lenalidomide treatment. Activin A showed a trend towards increasing levels in four patients, two of which were statistically significant. treatment further augmented increased activin A secretion when added to OB in coculture with MOLP5 cells (Figure 2b right panel) . Together, these data suggest that lenalidomide inhibits osteoblastogenesis in part by upregulating activin A secretion.
Lenalidomide induces activin A secretion via activation of the JNK pathway To determine the mechanism for lenalidomide-induced activin A secretion in BMSCs, we studied several signaling pathways. MM-derived BMSCs were incubated with lenalidomide (10 mM) for 30 min and 2 h. Protein expression of phospho-Akt, Akt, phospho-JNK, JNK, phospho-ERK1/2, ERK1/2 and GAPDH was assessed by western blot. Lenalidomide inhibited Akt and ERK phosphorylation and increased JNK phosphorylation (Figure 3a) . mRNA expression of c-Jun, INHbA and GAPDH was assessed by reverse transcription PCR. Lenalidomide increased c-Jun mRNA expression, without significant effect on INHbA, as shown on gels and confirmed by densitometric analysis (Figure 3b) . To understand whether the effect of lenalidomide on JNK signaling was related to Akt regulation, we treated BMSCs with an Akt inhibitor. MM-derived BMSCs were incubated with Akt inhibitor (1 mM) for 30 min and 4 h. Lenalidomide-induced inhibition of OB differentiation may be abrogated by the addition of an activin A-neutralizing antibody We next evaluated the potential effect of lenalidomide administered in combination with an activin A-neutralizing antibody. MM patient-derived BMSCs were cultured for 48 h in the presence of either lenalidomide (2 and 10 mM), activin A-neutralizing antibody (1 mg/ml), or a combination of the two. Lenalidomide decreased the proliferation of MM.1S in coculture with BMSCs, whereas no significant effect on proliferation was noted in the presence of activin A-neutralizing antibody as demonstrated by thymidine uptake (Supplementary Figure S1) . Importantly, the effect of activin A was reversed by adding lenalidomide. Consequently, we evaluated the ALP activity of lenalidomide and/or activin A-neutralizing antibody on OB cultured either alone (Figure 4a left panel) or in the presence of MOLP5 MM cells (Figure 4b left panel) . OB were differentiated for 1 week in the presence of either lenalidomide (10 mM), activin A-neutralizing antibody (1 mg/ml) or a combination of the two. ALP activity was then detected with a chromogenic substrate, and corrected for the number of viable cells quantified by Alamar Blue assay to establish API. Lenalidomide decreased the API; however, the effect was reversed by activin A-neutralizing antibody. We then quantified by ELISA the concentration of activin A in the supernatant from the same experiments. Lenalidomide increased activin A levels in OB (Figure 4b 
Lenalidomide in combination with an activin A-neutralizing antibody T Scullen et al
Activin A-neutralizing antibody reverses the effect of lenalidomide on the major signaling pathways involved in OB differentiation To further delineate the underlying mechanism, we investigated the effect of lenalidomide on activin A signaling in OB. OB were differentiated for 1 week in the presence of either lenalidomide (10 mM) or a combination of lenalidomide (10 mM) and activin A-neutralizing antibody (1 mg/ml). Protein expression of phospho-SMAD1/5/8, SMAD5, phospho-SMAD2, SMAD2, phospho-P38, P38 and GAPDH was assessed by western blot. Relative to their controls, OB differentiated in the presence of lenalidomide exhibited significant increases in the phosphorylation of both SMAD2, as well as the mitogen-activated protein kinase p38. Importantly, the effects of lenalidomide on SMAD2 and p38 were reversed by concurrent administration of activin A-neutralizing antibody ( Figure 5 left panel) . We next evaluated DLX5 expression by quantitative PCR. DLX5 is a RUNX2 activator that has a crucial role in osteogenesis by promoting OB proliferation and differentiation.
14 Lenalidomide, as expected, significantly repressed the mRNA DXL5 expression. Moreover, the effects of lenalidomide on DLX5 were reversed by concurrent administration of activin A-neutralizing antibody ( Figure 5 right panel) .
DISCUSSION
MM is characterized by the interaction of malignant plasma cells with stromal cells. This interaction results in osteoclast (OC) recruitment and activation, 15 inhibition of the differentiation of OB precursors and induction of mature OB apoptosis, promoting defective bone remodeling. 3, 16 Successful and novel treatments try to combine agents targeting tumor cell growth with drugs that target both the tumor and the bone microenvironment.
Lenalidomide is a thalidomide analog with improved tolerability profile and anticancer properties compared with thalidomide. 17 It is an approved MM therapy when combined with dexamethasone, based on results of two randomized phase III trials comparing the combination of lenalidomide/dexamethasone (len-dex) vs placebo/dexamethasone in patients with refractory/relapsed MM. 18, 19 The mechanism of action of lenalidomide has been extensively studied in MM. Lenalidomide has been shown to have direct antitumor activity and to disrupt MM cell-microenviroment interaction. 20 Lenalidomide acts on the BM microenvironment by inhibiting the secretion of pro-tumoral cytokines from stromal cells and affecting the survival and migration of tumor cells.
17,21
Figure 4. Activin A-neutralizing antibody reversed the inhibition of OB differentiation induced by lenalidomide. (a) OB were differentiated for 1 week in the presence of either lenalidomide (10 mM), activin A-neutralizing antibody (1 mg/ml) or a combination of the two. ALP activity was then detected with a chromogenic substrate and corrected for the number of viable cells quantified by Alamar Blue assay to establish API (left panel). Activin A concentrations in supernatants were quantified by ELISA (right panel). Activin A concentration level in BMSCs control was 101576.6 ± 2324.9 pg/ml. Activin A concentrations are expressed as percentage of control. (b) OB were cultured in the presence of MOLP5 MM cells with lenalidomide (10 mM) and/or activin A-neutralizing antibody (1 mg/ml). ALP activity was then detected as previously described (left panel) and activin A concentrations in supernatants were quantified by ELISA (right panel). Activin A concentration level in BMSCs control was 4226.3±256.7 pg/ml. Activin A concentrations are expressed as percentage of control. Figure 5 . The effect of Lenalidomide on SMAD pathway was reversed by the activin A-neutralizing antibody. OB were differentiated for 1 week in the presence of either lenalidomide (10 mM), or a combination of lenalidomide (10 mM) and activin A-neutralizing antibody (1 mg/ml). Protein expression of phospho-SMAD1/5/8, SMAD5, phospho-SMAD2, SMAD2, phospho-P38, P38 and GAPDH was assessed by western blot (left). mRNA expression of DLX5 was assessed via quantitative PCR (right).
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The OC compartment represents a critical component of BM. Lenalidomide has been studied in vitro for its effects on osteoclastogenesis. 6 It downregulates the secretion of major osteoclastogenetic mediators produced by BMSCs, such as interleukin-6, macrophage inflammatory protein 1-a and receptor activator of NF-kB ligand, and induces a reduction in OC expression of aVb3-integrin, a marker of OC differentiation, and Cathepsin K, a protease involved in matrix degradation. 6 However, in the context of bone formation, lenalidomide does not affect OB differentiation, as demonstrated by the fact that ALP activity and mineralized nodule formation remain unaffected. 22 No effect on Runx2 and osterix transcription was demonstrated either. 23 Lenalidomide has also been shown to be ineffective on OB function. 24 We observed that lenalidomide significantly stimulated activin A secretion from BMSCs in a dose-dependent manner. We have previously shown that MM-derived BMSCs secrete high levels of activin A, which in turn promotes osteoclastogenesis and inhibits OB differentiation. 7 Exploring further, we next quantified activin A concentrations in the plasma of BM aspirates obtained from MM patients who were on lenalidomide treatment. Samples were taken before starting lenalidomide and after several weeks of treatment. Of the six patients tested, four showed an increase in activin A levels, two of which were statistically significant, confirming that lenalidomide results in increased activin A secretion. Given the known effects of activin A on bone remodeling, 7, 25, 26 we next investigated effects of lenalidomide on osteoblastogenesis. As expected, in vitro differentiation of BMSCs into OB was in part inhibited in the presence of lenalidomide, which was even more pronounced in the context of MM-induced decrease in ALP activity. This was associated with an increase in activin A levels with lenalidomide alone and lenalidomide in the presence of MM cells. These data suggest that lenalidomide inhibits osteoblastogenesis in part by upregulating activin A secretion.
In order to determine a possible mechanism for lenalidomide induced activin A secretion by BMSCs, we studied several signaling pathways. On the basis of previous studies showing that activin A secretion in MM cells in coculture with BMSCs was associated with JNK pathway activation 7 and the presence of a highly conserved c-Jun-binding sequence in the promoter of the constituent subunit of the peptide, INHbA, 27 the JNK pathway was of particular interest. Accordingly, BMSCs treated with lenalidomide demonstrated an early activation of JNK signaling evidenced by increases in both JNK phosphorylation and c-Jun mRNA expression. Additionally, a marked decrease in Akt phosphorylation was observed. This led us to believe that Akt may negatively regulate JNK signaling in BMSCs, which in turn may govern peptide secretion and subsequent self-stimulation. In order to test this hypothesis, we first treated BMSCs with an Akt inhibitor, which resulted in stimulating JNK signaling along with both the release of activin A and the expression of INHbA. Conversely, abrogation of JNK phosphorylation in BMSCs by the JNK inhibitor resulted in a significant decrease in activin A secretion. These findings suggest that activin A secretion by BMSCs is in part induced by lenalidomide treatment in MM patients and occurs via an Akt-mediated JNK activation, although other pathways may be involved.
Given these data, we next evaluated the potential effect of lenalidomide administered in combination with an activin A-neutralizing antibody. As expected, activin A-neutralizing antibody had no significant impact on the direct antitumor activity of lenalidomide. Consequently ALP ELISAs showed a significant increase in API in OB treated with combined activin A-neutralizing antibody and lenalidomide compared with OB treated with lenalidomide. This effect was more evident when OB were cocultured with MOLP5 and directly correlated with activin A repression. The effect of lenalidomide on OB differentiation was partially reversed by activin A-neutralizing antibody, suggesting that OB suppressive effects of lenalidomide are only in part dependent on activin A. Lenalidomide increased activin A levels in OB and OB cocultured with MOLP5, and this effect was reversed by activin A-neutralizing antibody.
To further delineate the underlying mechanism, we investigated the effect of lenalidomide on activin A signaling in OB. Activin A activates the SMAD signaling pathway by binding activin A receptors type II (ActRIIA) that recruits type I receptor (usually ALK4). The activation of SMAD signaling induces the nuclear translocation of Smad4 that initiates specific gene transcription. 28, 29 Relative to their controls, OB differentiated in the presence of lenalidomide exhibited significant increases in the phosphorylation of both SMAD2, as well as the mitogen-activated protein kinase p38, reported to be positively associated with activin A binding. 30 DLX5 is a main target of the SMAD pathway considered a modulator of OB differentiation. 29 On the basis of our previous studies, 7 we evaluated DLX5 expression which, as expected, was repressed. The intracellular events in OB have been shown to be mediated by activin A binding. 7 Thus, by sequestering activin A extracellularly and preventing its binding, we can explain the observed repurcussions in SMAD and DLX5 signaling. Importantly, the effects of lenalidomide on SMAD2, p38 and DLX5 were reversed by concurrent administration of activin A-neutralizing antibody.
Collectively, these results suggest that the inhibition of osteoblastogenesis by lenalidomide treatment is in part activin A mediated. Concurrent administration of lenalidomide with an activin A-neutralizing antibody was able to overcome this effect. Lenalidomide is a potent immunomodulatory drug whose direct antitumor effects and indirect inhibition of osteoclastogenesis are of benefit in the treatment of MM. Combining it with an antiactivin A strategy, based on our data, is an obvious next step and is the subject of an ongoing clinical trial.
In addition to bone anabolic effects, an important aspect of targeting activin A includes effects on erythropoiesis. The soluble form of activin A receptor (Acceleron Pharma, Cambridge, MA, USA), RAP-011, has been extensively evaluated in preclinical studies, in particular in mouse models of cancer-and osteoporosis-related bone loss, and has shown a bone anabolic effect. 31 Importantly, in several mouse models, RAP-011 has shown an increase in the hematocrit levels in the RAP-011-treated mice compared with the control. [31] [32] [33] In fact, activin A induces hemoglobin synthesis directly and erythroid cell proliferation and DNA synthesis indirectly via accessory BM cells. 34, 35 Sotatercept, the human counterpart of the soluble activin receptor, has also shown increase in hemoglobin levels in healthy volunteers and in post menopausal women. 36 In contrast, grade 3-4 anemia was among the most frequently reported adverse effects in patients with refractory relapsed MM on lenalidomide monotherapy. 37, 38 Therefore, in the clinical setting, combination therapy may additionally have a beneficial effect on the lenalidomide-induced anemia toxicity.
Sotatercept has already been tested in a phase II trial in MM and has shown increase in markers of bone formation. 39 This trial allowed patients to continue a bisphosphonate, and therefore effects on bone were not necessarily related to sotatercept. Our ongoing trial will help demonstrate effects on the bone microenvironment in the context of sotatercept alone, and will be the first proof of concept trial demonstrating bone anabolic effects.
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